Biotechnology Weekly Update – January 18, 2024
🔷Dyne’s Muscle-Disorder Drugs' Trial Data, Strong Balance Sheet Driving The Stock
Dyne has bolstered its balance sheet with $345.1 Mln from an underwritten public offering that closed recently. The next update on the clinical trials is due in H2 2024.
https://www.rttnews.com/Products/BiotechInvestor/story.aspx?id=3400932&type=bimb
🔷Solid Biosciences On A Solid Footing, Up 45% In 6 Months
Solid Biosciences is set to begin patient dosing in phase I/II trial of its Duchenne muscular dystrophy gene therapy candidate, SGT-003, in mid-to-late Q1 2024.
https://www.rttnews.com/products/biotechinvestor/Story.aspx?ID=3410312&PageNum=7&type=bipm
🔷Takeda's HyQvia Secures FDA Approval for Second Indication After a Decade
HyQvia, approved for Primary Immunodeficiency Syndrome in 2014, has now won expanded approval for use as a maintenance therapy for adults with CIDP.
https://www.rttnews.com/3416946/takeda-announces-fda-approval-of-hyqvia-for-cidp-quick-facts.aspx
🔷Should You Keep An Eye On YMAB?
Y-mAbs anticipates Danyelza, its core drug, to achieve $80-85 Mln in net product revenue for 2023, driven by U.S. momentum and a growing global commercial footprint.
https://www.rttnews.com/Products/BiotechInvestor/story.aspx?id=3390631&type=bipm
🔷FDA Authorizes First AI Diagnostic Tool For Idiopathic Pulmonary Fibrosis
Imvaria's Fibresolve, an AI biomarker, aids in classifying suspected lung fibrosis, allowing early-stage diagnosis and facilitating timely treatment decision.
https://finance.yahoo.com/news/imvaria-announces-fda-novo-marketing-133000040.html
Subscribe to RTT Biotech Investor to get timely updates on Biotech & Pharma industry, and access all the timely news, time-sensitive information, and alerts that can enable you to make sound investment decisions.
https://bit.ly/3G5cWiS
Follow us on
Instagram - https://www.instagram.com/rttnews
Twitter- https://twitter.com/rttnews
Facebook- https://www.facebook.com/RTTTopStories
YouTube - https://www.youtube.com/rttnews
#biotech #biotechnology #rttnews #FDA #weeklyupdates #weeklynews #fdaapproved #fdaapproval
🔷Dyne’s Muscle-Disorder Drugs’ Trial Data, Strong Balance Sheet Driving The Stock
Dyne has bolstered its balance sheet with $345.1 Mln from an underwritten public offering that closed recently. The next update on the clinical trials is due in H2 2024.
https://www.rttnews.com/Products/BiotechInvestor/story.aspx?id=3400932&type=bimb
🔷Solid Biosciences On A Solid Footing, Up 45% In 6 Months
Solid Biosciences is set to begin patient dosing in phase I/II trial of its Duchenne muscular dystrophy gene therapy candidate, SGT-003, in mid-to-late Q1 2024.
https://www.rttnews.com/products/biotechinvestor/Story.aspx?ID=3410312&PageNum=7&type=bipm
🔷Takeda’s HyQvia Secures FDA Approval for Second Indication After a Decade
HyQvia, approved for Primary Immunodeficiency Syndrome in 2014, has now won expanded approval for use as a maintenance therapy for adults with CIDP.
https://www.rttnews.com/3416946/takeda-announces-fda-approval-of-hyqvia-for-cidp-quick-facts.aspx
🔷Should You Keep An Eye On YMAB?
Y-mAbs anticipates Danyelza, its core drug, to achieve $80-85 Mln in net product revenue for 2023, driven by U.S. momentum and a growing global commercial footprint.
https://www.rttnews.com/Products/BiotechInvestor/story.aspx?id=3390631&type=bipm
🔷FDA Authorizes First AI Diagnostic Tool For Idiopathic Pulmonary Fibrosis
Imvaria’s Fibresolve, an AI biomarker, aids in classifying suspected lung fibrosis, allowing early-stage diagnosis and facilitating timely treatment decision.
https://finance.yahoo.com/news/imvaria-announces-fda-novo-marketing-133000040.html
Subscribe to RTT Biotech Investor to get timely updates on Biotech & Pharma industry, and access all the timely news, time-sensitive information, and alerts that can enable you to make sound investment decisions.
https://bit.ly/3G5cWiS
Follow us on
Instagram – https://www.instagram.com/rttnews
Twitter- https://twitter.com/rttnews
Facebook- https://www.facebook.com/RTTTopStories
YouTube – https://www.youtube.com/rttnews
#biotech #biotechnology #rttnews #FDA #weeklyupdates #weeklynews #fdaapproved #fdaapproval
